04Jun/13

Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell … – MarketWatch

Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell
MarketWatch
Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell Transplant with or without REVLIMID Maintenance in Newly-Diagnosed Multiple Myeloma Presented at ASCO. MEL200 demonstrated a longer median PFS and OS compared
MEL200 demonstrated a longer median PFS and OS compared to MPR in the Investor’s Business Daily
ASCO 2012 Multiple Myeloma Update – Day Three: Poster PresentationsThe Myeloma Beacon

all 9 news articles »

03Jun/13

Study Evaluating REVLIMID® Combination Compared to Autologous Stem Cell … – Business Wire (press release)

Study Evaluating REVLIMID® Combination Compared to Autologous Stem Cell
Business Wire (press release)
today announced data from a study comparing melphalan, prednisone and REVLIMID (lenalidomide) (MPR) with high-dose chemotherapy and tandem autologous stem cell transplant (MEL200), as well as evaluating the effect of lenalidomide maintenance
ASCO 2013 Multiple Myeloma Update – Day Two: Education SessionThe Myeloma Beacon

all 3 news articles »